The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]
BCL2 protein affects the susceptibility to tetrandrine tetrandrine results in increased expression of BCL2 protein CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein] tetrandrine results in decreased expression of BCL2 mRNA; tetrandrine results in decreased expression of BCL2 protein
tetrandrine results in increased expression of BECN1 protein [sodium arsenite co-treated with tetrandrine] results in increased expression of BECN1 protein tetrandrine results in decreased expression of BECN1 protein
tetrandrine results in increased expression of CASP3 protein tetrandrine results in increased cleavage of CASP3 protein 3-methyladenine inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]; tetrandrine results in increased cleavage of and results in increased activity of CASP3 protein
tetrandrine results in increased cleavage of and results in increased activity of CASP8 protein tetrandrine results in increased expression of CASP8 protein tetrandrine results in increased cleavage of CASP8 protein
tetrandrine results in increased cleavage of and results in increased activity of CASP9 protein tetrandrine results in increased cleavage of CASP9 protein
[sodium arsenite co-treated with tetrandrine] affects the expression of CCND1 protein; [sodium arsenite co-treated with tetrandrine] results in decreased expression of CCND1 protein tetrandrine results in decreased expression of CCND1 protein tetrandrine affects the expression of CCND1 protein
tetrandrine results in increased expression of CDKN1A tetrandrine affects the expression of CDKN1A protein [sodium arsenite co-treated with tetrandrine] affects the expression of CDKN1A protein
[sodium arsenite co-treated with tetrandrine] results in increased expression of CDKN1B protein tetrandrine results in increased expression of CDKN1B protein
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]
[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; [tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]
[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 protein]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein
CYP3A5 protein results in increased glutathionylation of tetrandrine CYP3A5 protein results in increased susceptibility to tetrandrine CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione]; CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]
[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of FOXO3 protein; [sodium arsenite co-treated with tetrandrine] results in increased expression of FOXO3 protein; tetrandrine affects the expression of and affects the phosphorylation of FOXO3 protein
[tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]; resveratrol inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] tetrandrine results in increased expression of ICAM1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [[arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tetrandrine results in increased expression of ICAM1 protein]; [arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein; [arsenite co-treated with tetrandrine] results in increased expression of ICAM1 protein
[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein] tetrandrine results in decreased expression of IL17A mRNA
tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein] tetrandrine results in increased phosphorylation of MAPK1 protein [arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK1 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK1 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] tetrandrine results in increased phosphorylation of MAPK3 protein [arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK3 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK3 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]
tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein] tetrandrine results in decreased expression of MMP9 protein
[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine results in decreased expression of and results in decreased phosphorylation of MTOR protein tetrandrine results in decreased expression of MTOR protein; tetrandrine results in decreased expression of MTOR protein modified form
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein] tetrandrine results in decreased expression of and results in decreased activity of RELA protein tetrandrine results in increased phosphorylation of RELA protein
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA] tetrandrine results in decreased expression of RORC mRNA
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]
BIRC5 protein results in decreased susceptibility to Noscapine Noscapine results in increased expression of BIRC5 mRNA; Noscapine results in increased expression of BIRC5 protein Noscapine results in decreased expression of BIRC5 protein Noscapine promotes the reaction [Cisplatin results in decreased expression of BIRC5 protein]
[Noscapine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP3 protein]; Noscapine results in increased expression of and results in increased cleavage of CASP3 protein Noscapine results in increased activity of CASP3 protein
Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP9 protein]; Noscapine results in increased expression of and results in increased cleavage of CASP9 protein
Noscapine promotes the reaction [Cisplatin results in increased expression of CDKN1A protein] Noscapine results in increased expression of CDKN1A protein
Noscapine promotes the reaction [Cisplatin results in increased expression of TP53 protein]; Noscapine results in increased expression of and results in increased phosphorylation of TP53 protein Noscapine results in increased expression of TP53 protein
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]
ACHE protein results in increased chemical synthesis of 6-O-monoacetylmorphine [ACHE protein results in increased degradation of 6-O-monoacetylmorphine] which results in increased chemical synthesis of Morphine; [ACHE protein results in increased metabolism of Heroin] which results in increased chemical synthesis of 6-O-monoacetylmorphine
[BCHE protein results in increased degradation of 6-O-monoacetylmorphine] which results in increased chemical synthesis of Morphine; [BCHE protein results in increased metabolism of Heroin] which results in increased chemical synthesis of 6-O-monoacetylmorphine BCHE protein results in increased chemical synthesis of 6-O-monoacetylmorphine
6-O-monoacetylmorphine binds to CES1 protein Cocaine inhibits the reaction [CES1 protein results in increased chemical synthesis of 6-O-monoacetylmorphine]
CES2 protein results in increased hydrolysis of 6-O-monoacetylmorphine Cocaine inhibits the reaction [CES2 protein results in increased chemical synthesis of 6-O-monoacetylmorphine]; Cocaine inhibits the reaction [CES2 protein results in increased hydrolysis of 6-O-monoacetylmorphine]
Apomorphine results in increased secretion of and results in increased activity of AMY1A protein; Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Metoclopramide inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]
Apomorphine results in increased expression of AVP protein Metoclopramide inhibits the reaction [Apomorphine results in increased expression of AVP protein]
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]
Apomorphine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein] [[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]
[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein] DRD2 protein affects the susceptibility to Apomorphine DRD2 protein results in increased susceptibility to Apomorphine
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] Apomorphine results in decreased secretion of HAMP protein modified form Apomorphine results in decreased expression of HAMP mRNA
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]
HTR6 protein results in increased susceptibility to Apomorphine Ro4368554 inhibits the reaction [HTR6 protein results in increased susceptibility to Apomorphine]
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Berberine inhibits the reaction [acetamiprid results in increased activity of ACHE protein] Berberine results in decreased activity of ACHE protein
Berberine results in decreased expression of ACTA2 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA]
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA]
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of BAX mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein]
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein]
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]
Berberine results in increased expression of BNIP3L protein [Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein] Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of CASP3 mRNA] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA
Berberine results in increased cleavage of CASP9 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP9 protein] [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [acetamiprid results in decreased activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of CAT protein]
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein]
Berberine results in increased expression of CD36 mRNA Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA]
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein]
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA; Berberine results in decreased expression of CEBPA protein
Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CEBPB mRNA
Berberine results in increased expression of COL1A1 mRNA Berberine inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA]
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]
Berberine results in decreased cleavage of CTSL protein Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]
Berberine results in increased expression of CYP2B10 mRNA Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA]
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]
Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein
Berberine results in decreased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA]
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of FN1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein]
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein]
Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of GSR protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein]
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form]
Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein]
Berberine results in increased expression of HMOX1 protein Berberine results in increased expression of HMOX1 mRNA; Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of HMOX1 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein]
Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein] [Chloroquine co-treated with Berberine] results in decreased expression of IGF2BP3 protein; Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]; Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein]
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA]
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased localization of MAP1LC3B protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of MAP1LC3B mRNA]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA]
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MIR142 mRNA]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein]
Berberine results in decreased activity of MMP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]
Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR mRNA]; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR protein]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]
Berberine results in increased expression of NFE2L2 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of NFE2L2 protein] Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein]
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein]
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein]
Berberine results in increased activity of PPARD protein Berberine results in increased expression of PPARD mRNA; Berberine results in increased expression of PPARD protein
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] Berberine results in decreased expression of PPARG mRNA; Berberine results in decreased expression of PPARG protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA]
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein]
Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 mRNA]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 protein]
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of SOD1 protein]
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [acetamiprid results in decreased expression of SOD2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA]
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein]
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of STAT3 mRNA]
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of TGFB1 mRNA] Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Dietary Fats results in increased secretion of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of TNF protein]
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]
[beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] inhibits the reaction [Morphine results in increased abundance of 3,4-Dihydroxyphenylacetic Acid]; [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] inhibits the reaction [Morphine results in increased abundance of Homovanillic Acid]; [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Morphine [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Nicotine
Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form] Bicuculline results in decreased expression of GABRA1 mRNA
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]
Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]] Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]
Bicuculline results in decreased expression of GABRB3 mRNA Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]
Bicuculline affects the reaction [bisphenol A affects the secretion of GNRH1 protein]; Bicuculline promotes the reaction [manganese chloride results in increased secretion of GNRH1 protein]
Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; Bicuculline results in decreased expression of and results in decreased localization of GRIA2 protein; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline results in decreased expression of GRIA2 mRNA; Bicuculline results in decreased expression of GRIA2 protein
Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK1 protein] [Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein]
Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK3 protein] [Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]
MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline results in increased phosphorylation of MECP2 protein Bicuculline results in increased expression of MECP2 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]
Bicuculline inhibits the reaction [Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Bicuculline inhibits the reaction [Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]
[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]
Bicuculline promotes the reaction [Reserpine affects the activity of TH protein]; Bicuculline promotes the reaction [Reserpine results in increased expression of TH mRNA]
Buprenorphine results in decreased activity of CAT protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Buprenorphine] results in increased activity of CAT protein
CYP3A4 protein affects the metabolism of Buprenorphine CYP3A4 protein results in decreased alkylation of Buprenorphine CYP3A4 protein results in increased metabolism of Buprenorphine Buprenorphine results in decreased activity of CYP3A4 protein
Buprenorphine binds to and affects the activity of OPRM1 protein; Buprenorphine binds to and results in increased activity of OPRM1 protein; Buprenorphine inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] Buprenorphine binds to OPRM1 protein
chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] chelerythrine results in decreased activity of ABCB11 protein
chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein]
chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]] chelerythrine inhibits the reaction [Resveratrol affects the expression of BCL2 protein]
malonic acid inhibits the reaction [chelerythrine results in increased activity of CASP3 protein]; Rotenone inhibits the reaction [chelerythrine results in increased activity of CASP3 protein] Acetylcysteine inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; Dithiothreitol inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; S-methyl glutathione inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]
malonic acid inhibits the reaction [chelerythrine results in increased activity of CASP9 protein]; Rotenone inhibits the reaction [chelerythrine results in increased activity of CASP9 protein] chelerythrine results in increased cleavage of CASP9 protein
chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
chelerythrine inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; chelerythrine promotes the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]
chelerythrine inhibits the reaction [EGF protein inhibits the reaction [Acetaldehyde affects the localization of TJP1 protein]]; chelerythrine inhibits the reaction [EGF protein results in decreased susceptibility to Acetaldehyde]
chelerythrine inhibits the reaction [Acrolein results in increased secretion of GPT protein]; chelerythrine inhibits the reaction [allyl alcohol results in increased secretion of GPT protein]
chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of IL1B mRNA]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of IL1B protein]
chelerythrine inhibits the reaction [Acids results in increased expression of IL6 mRNA]; chelerythrine inhibits the reaction [Acids results in increased secretion of IL6 protein] chelerythrine inhibits the reaction [Ethanol results in increased expression of IL6 protein]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of IL6 mRNA]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of IL6 protein]
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] chelerythrine inhibits the reaction [Estradiol results in increased activity of MAPK1 protein] chelerythrine inhibits the reaction [CXCL8 protein results in increased phosphorylation of MAPK1 protein]
chelerythrine inhibits the reaction [CXCL8 protein results in increased phosphorylation of MAPK3 protein] chelerythrine inhibits the reaction [Estradiol results in increased activity of MAPK3 protein] chelerythrine inhibits the reaction [[Lead co-treated with Lipopolysaccharides] results in increased phosphorylation of MAPK3 protein]; chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
chelerythrine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; chelerythrine promotes the reaction [2-aminoethoxydiphenyl borate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]
chelerythrine inhibits the reaction [Calcium results in increased phosphorylation of PRKCE protein] [chelerythrine results in decreased activity of PRKCE protein] which results in decreased susceptibility to Phenylephrine
chelerythrine inhibits the reaction [Acids results in increased activity of RELA protein]; chelerythrine inhibits the reaction [Glucose results in increased activity of RELA protein] chelerythrine inhibits the reaction [Ethanol results in increased expression of RELA protein]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of RELA protein]
chelerythrine results in decreased activity of SLC1A1 protein chelerythrine inhibits the reaction [Pregabalin results in increased activity of SLC1A1 protein]; chelerythrine inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]
chelerythrine inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of TH mRNA]; chelerythrine inhibits the reaction [HU 211 results in decreased expression of TH mRNA]
chelerythrine inhibits the reaction [Ethanol results in increased expression of TNF protein]; chelerythrine inhibits the reaction [lead acetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; chelerythrine inhibits the reaction [lead acetate results in increased expression of TNF protein]; chelerythrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TNF mRNA]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of TNF protein]; chelerythrine inhibits the reaction [TNF protein results in increased transport of Chlorides]; chelerythrine inhibits the reaction [TNF protein results in increased transport of Potassium]
CYP2C19 protein results in increased metabolism of chelidonine [CYP2C19 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog
CYP2D6 protein results in increased metabolism of chelidonine [CYP2D6 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog
CYP3A4 protein results in increased metabolism of chelidonine [CYP3A4 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog
CYP2D6 protein affects the metabolism of Codeine; CYP2D6 protein polymorphism affects the metabolism of Codeine [CYP2D6 gene mutant form results in increased activity of CYP2D6 protein] which results in increased susceptibility to Codeine; [CYP2D6 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of Morphine [CYP2D22 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of norcodeine CYP2D6 protein polymorphism affects the susceptibility to Codeine CYP2D6 protein results in decreased methylation of Codeine CYP2D6 gene polymorphism results in increased metabolism of Codeine; CYP2D6 protein results in increased metabolism of Codeine
CYP3A4 protein affects the metabolism of Codeine CYP3A4 protein results in increased metabolism of Codeine [CYP3A4 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of norcodeine
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased activity of GPT protein]]; corynoline inhibits the reaction [Zearalenone results in increased activity of GPT protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline promotes the reaction [Zearalenone results in increased expression of HMOX1 protein]]; corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; corynoline promotes the reaction [Zearalenone results in increased expression of HMOX1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased expression of IL1B protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; corynoline inhibits the reaction [Zearalenone results in increased expression of IL1B protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased activity of MPO protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of MPO protein]; corynoline inhibits the reaction [Zearalenone results in increased activity of MPO protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline promotes the reaction [Zearalenone results in increased expression of NFE2L2 protein]]; corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFE2L2 protein]; corynoline promotes the reaction [Zearalenone results in increased expression of NFE2L2 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of NFKBIA protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]; corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of NFKBIA protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of RELA protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]; corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of RELA protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in decreased expression of SIRT1 protein]]; corynoline inhibits the reaction [Zearalenone results in decreased expression of SIRT1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased expression of TNF protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; corynoline inhibits the reaction [Zearalenone results in increased expression of TNF protein]
CYP3A4 protein results in increased glutathionylation of dauricine [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of N-desmethyldauricine; [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of quinone methide; CYP3A4 protein results in increased oxidation of and results in increased activity of dauricine; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased glutathionylation of dauricine]
Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in increased expression of BAX protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased expression of BAX protein]
Dextromethorphan results in decreased expression of BCL2L1 protein Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in decreased expression of BCL2L1 protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in decreased expression of BCL2L1 protein]
Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in increased cleavage of CASP3 protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased cleavage of CASP3 protein]
CYP2D2 protein results in decreased methylation of Dextromethorphan [CYP2D2 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan
CYP2D6 polymorphism affects the metabolism of Dextromethorphan; CYP2D6 protein affects the metabolism of Dextromethorphan; CYP2D6 protein polymorphism affects the metabolism of Dextromethorphan CYP2D6 protein results in decreased methylation of Dextromethorphan CYP2D6 mRNA results in increased metabolism of Dextromethorphan; CYP2D6 protein results in increased metabolism of Dextromethorphan [CYP2D22 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan; Ketoconazole inhibits the reaction [CYP2D22 protein results in increased metabolism of Dextromethorphan] Dextromethorphan results in decreased activity of CYP2D6 protein Cimetidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; ozagrel promotes the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan] [5-bromotryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [5-chlorotryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [5-fluoro-alpha-methyltryptamine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [5-fluorotryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [5-methyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [7-methyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [CYP2D6 mRNA results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan; [CYP2D6 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan; [Fluoxetine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [indopan analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [indopan results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [Methoxydimethyltryptamines analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [Tryptamines analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; Nicardipine inhibits the reaction [CYP2D6 protein results in decreased methylation of Dextromethorphan]; notopterol inhibits the reaction [[CYP2D6 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan]; notopterol inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Plant Extracts inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; raubasine inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]; Resveratrol inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; sarpogrelate inhibits the reaction [CYP2D6 protein results in decreased methylation of Dextromethorphan]; sarpogrelate metabolite inhibits the reaction [CYP2D6 protein results in decreased methylation of Dextromethorphan]; serpentine (alkaloid) inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan] CYP2D6 gene polymorphism results in increased susceptibility to Dextromethorphan
CYP3A4 protein results in decreased methylation of Dextromethorphan CYP3A4 protein results in increased oxidation of Dextromethorphan CYP3A4 protein results in increased metabolism of Dextromethorphan Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein] CYP3A4 protein affects the metabolism of Dextromethorphan
CYP3A5 protein affects the metabolism of Dextromethorphan CYP3A5 protein results in increased oxidation of Dextromethorphan CYP3A5 protein results in decreased methylation of Dextromethorphan
Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in increased expression of FOS protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased expression of FOS protein] Dextromethorphan inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of FOS]
Dextromethorphan affects the expression of GCLC mRNA PRKCD protein affects the reaction [Dextromethorphan affects the expression of GCLC mRNA]; rostafuroxin affects the reaction [Dextromethorphan affects the expression of GCLC mRNA]; rottlerin affects the reaction [Dextromethorphan affects the expression of GCLC mRNA]; traxoprodil mesylate affects the reaction [Dextromethorphan affects the expression of GCLC mRNA]
PRKCD protein affects the reaction [Dextromethorphan affects the expression of GCLM mRNA]; rostafuroxin affects the reaction [Dextromethorphan affects the expression of GCLM mRNA]; rottlerin affects the reaction [Dextromethorphan affects the expression of GCLM mRNA]; traxoprodil mesylate affects the reaction [Dextromethorphan affects the expression of GCLM mRNA]
Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]
Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in increased expression of GRIN2B protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased expression of GRIN2B protein] Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]; rostafuroxin inhibits the reaction [Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]]; rostafuroxin inhibits the reaction [Dextromethorphan results in increased expression of GRIN2B protein]; rottlerin inhibits the reaction [Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]]; traxoprodil mesylate inhibits the reaction [Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased expression of GRIN2B protein]
Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]] Dextromethorphan inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of JUN]
Dextromethorphan results in increased phosphorylation of MAPK1 protein rostafuroxin inhibits the reaction [Dextromethorphan results in increased phosphorylation of MAPK1 protein]
MRGPRX2 protein affects the susceptibility to Dextromethorphan MRGPRX2 protein affects the reaction [Dextromethorphan results in increased secretion of HEXB protein] Dextromethorphan binds to MRGPRX2 protein
[PRKCD protein affects the susceptibility to Dextromethorphan] which affects the activity of and affects the localization of NFE2L2 protein; [rostafuroxin co-treated with Dextromethorphan] results in increased activity of and affects the localization of NFE2L2 protein; [rottlerin co-treated with Dextromethorphan] results in increased activity of and affects the localization of NFE2L2 protein; [traxoprodil mesylate co-treated with Dextromethorphan] results in increased activity of and affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [Dextromethorphan results in increased activity of NFE2L2 protein]; Dextromethorphan results in increased activity of and affects the localization of NFE2L2 protein
[Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin
Dextromethorphan binds to OPRK1 protein [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin
[PRKCD protein affects the susceptibility to Dextromethorphan] which affects the activity of and affects the localization of NFE2L2 protein; Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]; Dextromethorphan results in increased expression of and results in increased phosphorylation of PRKCD protein; PRKCD protein affects the reaction [Dextromethorphan affects the expression of GCLC mRNA]; PRKCD protein affects the reaction [Dextromethorphan affects the expression of GCLM mRNA]; rostafuroxin inhibits the reaction [Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]]; rostafuroxin inhibits the reaction [Dextromethorphan results in increased phosphorylation of PRKCD protein]; rottlerin inhibits the reaction [Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]]; rottlerin inhibits the reaction [Dextromethorphan results in increased phosphorylation of PRKCD protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan promotes the reaction [PRKCD protein modified form binds to GRIN2B protein]]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased phosphorylation of PRKCD protein]
SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]] Dextromethorphan binds to SIGMAR1 protein
Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein]
Dextromethorphan results in decreased expression of TNF protein Dextromethorphan results in increased secretion of TNF protein Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dextromethorphan inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]
CYP2D2 protein results in increased chemical synthesis of Dextrorphan [CYP2D2 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan
CYP2D6 protein affects the chemical synthesis of Dextrorphan [CYP2D22 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan [CYP2D6 mRNA results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan; [CYP2D6 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan; notopterol inhibits the reaction [[CYP2D6 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]
Dextrorphan binds to OPRD1 protein [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin
[Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin
dimemorfan results in decreased expression of CCL2 protein dimemorfan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
CYP2D6 protein results in increased oxidation of dimemorfan Paroxetine inhibits the reaction [CYP2D6 protein results in increased oxidation of dimemorfan]
CYP3A4 protein results in increased oxidation of dimemorfan Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of dimemorfan]
dimemorfan inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of FOS] dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]
dimemorfan inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; dimemorfan inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGAM protein]
dimemorfan inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of JUN] dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]
dimemorfan inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] dimemorfan affects the expression of NOS2 protein
dimemorfan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of and results in increased activity of RELA protein]
dimemorfan binds to and results in increased activity of SIGMAR1 protein; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]] dimemorfan binds to SIGMAR1 protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK1 protein] MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]
Emetine results in increased phosphorylation of and results in increased activity of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein]
Emetine results in increased phosphorylation of MAPK3 protein Emetine results in decreased phosphorylation of MAPK3 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK3 protein]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK8 protein]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK9 protein]
Emetine results in decreased activity of MMP2 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein] Emetine results in decreased expression of MMP2 mRNA
Emetine results in decreased activity of MMP9 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein] Emetine results in decreased expression of MMP9 mRNA
fangchinoline results in increased expression of ATF4 protein Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of ATF4 protein]
fangchinoline results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of DDIT3 protein]
fangchinoline results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [fangchinoline results in increased expression of HSPA5 protein]
Heroin results in decreased expression of BDNF protein Heroin results in decreased expression of BDNF mRNA Heroin inhibits the reaction [CREB1 protein modified form binds to BDNF promoter]
[Heroin co-treated with Cocaine] results in increased activity of CASP3 protein; Heroin promotes the reaction [Cocaine results in increased activity of CASP3 protein]
CES1 protein results in decreased acetylation of Heroin CES1 protein results in increased hydrolysis of Heroin Cocaine inhibits the reaction [CES1 protein results in increased hydrolysis of Heroin] Heroin binds to CES1 protein
Heroin results in increased expression of FOS mRNA; Heroin results in increased expression of FOS protein Dronabinol affects the reaction [Heroin results in increased expression of FOS protein]
Hydromorphone results in increased activity of OPRM1 protein [Hydromorphone binds to and results in increased activity of OPRM1 protein] which results in increased activity of ARRB2 protein; Hydromorphone binds to and results in increased activity of OPRM1 protein
Levallorphan binds to OPRD1 protein [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin
Levallorphan binds to OPRK1 protein [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Levallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin
Levorphanol binds to OPRD1 protein [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Serotonin
Levorphanol binds to OPRK1 protein [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Levorphanol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRM1 protein] which results in decreased uptake of Serotonin
Morphine results in decreased expression of ACAT1 protein Morphine deficiency affects the reaction [Morphine results in decreased expression of ACAT1 protein]
[ACHE protein results in increased degradation of 6-O-monoacetylmorphine] which results in increased chemical synthesis of Morphine ACHE protein results in increased chemical synthesis of Morphine
ADCY8 protein affects the susceptibility to Morphine Morphine affects the expression of ADCY8 mRNA [ADCY8 protein co-treated with ADCY1 protein] affects the susceptibility to Morphine
ADORA1 protein affects the susceptibility to Morphine Morphine results in increased expression of ADORA1 mRNA; Morphine results in increased expression of ADORA1 protein [lead acetate co-treated with Morphine] results in increased expression of ADORA1 mRNA; [lead acetate co-treated with Morphine] results in increased expression of ADORA1 protein
[lead acetate co-treated with Morphine] results in increased expression of AIF1 mRNA corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]; Minocycline inhibits the reaction [Morphine results in increased expression of AIF1 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]
ARRB2 protein inhibits the reaction [Morphine results in decreased expression of AKT1 protein modified form] Morphine results in increased expression of AKT1 protein modified form Naloxone inhibits the reaction [Morphine results in increased expression of AKT1 protein modified form]
Morphine results in increased expression of APOE protein Morphine deficiency affects the reaction [Morphine results in increased expression of APOE protein]
morphine increases expression in Arc protein in nucleus accumbens morphine increases expression of Arc mRNA in prefrontal cortex morphine co-treated with naloxone increases expression of Arc protein in brain Morphine increases expression of Arc protein in shell of nucleus accumbens
ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of PPP1R1B protein]; Morphine promotes the reaction [ARL6IP5 protein binds to OPRD1 protein] Morphine results in increased expression of ARL6IP5 protein ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of PPP1R1B protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]]; Morphine promotes the reaction [ARL6IP5 protein binds to OPRD1 protein]
ARRB2 gene SNP affects the susceptibility to Morphine [Morphine binds to and results in increased activity of OPRM1 protein] which results in increased activity of ARRB2 protein ARRB2 protein affects the susceptibility to Morphine [gp120 protein, Human immunodeficiency virus 1 co-treated with Morphine] results in decreased expression of ARRB2 mRNA; [OPRM1 protein co-treated with Morphine] results in increased activity of ARRB2 protein; ARRB2 protein inhibits the reaction [Morphine results in decreased expression of AKT1 protein modified form]; ARRB2 protein inhibits the reaction [Morphine results in decreased expression of CASP8 protein alternative form]
Morphine deficiency affects the reaction [Morphine deficiency affects the reaction [Morphine results in increased expression of ART3 protein]]; Morphine deficiency affects the reaction [Morphine results in increased expression of ART3 protein]
corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]
[[Morphine results in increased expression of BAX protein] co-treated with [Morphine results in decreased expression of BCL2 protein]] results in increased activity of CASP3 protein; [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of BAX protein; Morphine inhibits the reaction [Dactinomycin results in increased expression of BAX protein]; Morphine inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in increased expression of BAX protein]]; PDGFB protein inhibits the reaction [Morphine results in increased expression of BAX protein] Morphine results in increased expression of BAX mRNA; Morphine results in increased expression of BAX protein Morphine results in decreased expression of BAX mRNA Lithium inhibits the reaction [Morphine results in increased expression of BAX mRNA] TGFB1 protein affects the reaction [Morphine results in increased expression of BAX protein]
BCHE protein results in increased chemical synthesis of Morphine [BCHE protein results in increased degradation of 6-O-monoacetylmorphine] which results in increased chemical synthesis of Morphine
[[Morphine results in increased expression of BAX protein] co-treated with [Morphine results in decreased expression of BCL2 protein]] results in increased activity of CASP3 protein; Morphine inhibits the reaction [BECN1 protein binds to BCL2 protein]; Morphine inhibits the reaction [Dactinomycin results in decreased expression of BCL2 protein]; Morphine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in decreased expression of BCL2 protein]]; PDGFB protein inhibits the reaction [Morphine results in decreased expression of BCL2 protein] Morphine results in decreased expression of BCL2 mRNA; Morphine results in decreased expression of BCL2 protein Lithium inhibits the reaction [Morphine results in decreased expression of BCL2 mRNA]
Morphine results in increased expression of BDNF mRNA; Morphine results in increased expression of BDNF protein Morphine increases expression of Bdnf mRNA in ventral tegmental area Morphine results in decreased expression of BDNF mRNA; Morphine results in decreased expression of BDNF mRNA alternative form Morphine inhibits the reaction [CREB1 protein modified form binds to BDNF promoter]; Morphine inhibits the reaction [NR4A2 protein binds to BDNF promoter]; Morphine inhibits the reaction [RING1 protein alternative form binds to BDNF promoter]; Morphine promotes the reaction [CREB1 protein binds to BDNF promoter]; Morphine promotes the reaction [EZH2 protein binds to BDNF promoter]; Morphine promotes the reaction [ING2 protein binds to BDNF promoter]; Morphine promotes the reaction [KMT2A protein binds to BDNF promoter]; Morphine promotes the reaction [SIN3A protein binds to BDNF promoter]; Morphine promotes the reaction [SUZ12 protein binds to BDNF promoter] AM 251 inhibits the reaction [Morphine results in increased expression of BDNF protein]; BDNF protein inhibits the reaction [NR4A2 protein affects the susceptibility to Morphine]; Curcumin inhibits the reaction [Morphine results in increased expression of BDNF mRNA]
Morphine results in increased expression of CALCA mRNA; Morphine results in increased expression of CALCA protein PENK protein alternative form inhibits the reaction [Morphine results in increased expression of CALCA protein] GRIK1 protein affects the reaction [Morphine results in increased expression of CALCA protein]
[[Morphine results in increased expression of BAX protein] co-treated with [Morphine results in decreased expression of BCL2 protein]] results in increased activity of CASP3 protein; Morphine inhibits the reaction [Doxorubicin results in increased cleavage of and results in increased activity of CASP3 protein]; Morphine results in increased activity of and results in increased cleavage of CASP3 protein; PDGFB protein inhibits the reaction [Morphine results in increased activity of CASP3 protein] Morphine results in increased cleavage of CASP3 protein Morphine results in increased expression of CASP3 protein Minocycline inhibits the reaction [Morphine results in increased activity of CASP3 protein] corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; Minocycline inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; Naloxone inhibits the reaction [Morphine results in increased activity of CASP3 protein]; Naloxone inhibits the reaction [Morphine results in increased expression of CASP3 protein alternative form]; SB 203580 inhibits the reaction [Morphine results in increased activity of CASP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]] Morphine results in increased expression of CASP3 protein; Morphine results in increased expression of CASP3 protein alternative form
ARRB2 protein inhibits the reaction [Morphine results in decreased expression of CASP8 protein alternative form] Morphine results in increased activity of CASP8 protein
beta-funaltrexamine inhibits the reaction [Morphine results in decreased expression of CCL5 protein]; Naloxone inhibits the reaction [Morphine results in decreased expression of CCL5 protein]
[Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of CDKN1A protein
CES2 protein results in increased chemical synthesis of Morphine Cocaine inhibits the reaction [CES2 protein results in increased chemical synthesis of Morphine]
[Morphine results in increased expression of CNR1 mRNA] which results in increased susceptibility to Dronabinol; Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA] Morphine deficiency results in decreased expression of CNR1 mRNA CTAP octapeptide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]
Morphine results in decreased expression of CREB1 mRNA AM 251 inhibits the reaction [Morphine results in increased phosphorylation of CREB1 protein]; suvorexant inhibits the reaction [Morphine results in increased expression of CREB1 protein] Morphine inhibits the reaction [CREB1 protein modified form binds to BDNF promoter]; Morphine inhibits the reaction [CREB1 protein modified form binds to NR4A2 promoter]; Morphine promotes the reaction [CREB1 protein binds to BDNF promoter]; Morphine promotes the reaction [CREB1 protein modified form binds to GRIA1 promoter]; Morphine promotes the reaction [CREB1 protein modified form binds to TH promoter] Morphine results in decreased phosphorylation of CREB1 protein
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased phosphorylation of MAPK1 protein]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased phosphorylation of MAPK3 protein]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased phosphorylation of TH protein]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased secretion of POMC protein modified form]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] which results in decreased susceptibility to Morphine deficiency CRHR1 gene mutant form inhibits the reaction [[Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein]
Morphine results in increased secretion of CYCS protein Morphine results in decreased secretion of CYCS protein Morphine inhibits the reaction [Doxorubicin affects the localization of CYCS protein]
CYP2D6 protein affects the chemical synthesis of Morphine Morphine results in increased activity of CYP2D6 protein [CYP2D6 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of Morphine
Morphine deficiency affects the reaction [Morphine deficiency affects the reaction [Morphine results in increased expression of DDAH2 protein]]; Morphine deficiency affects the reaction [Morphine results in increased expression of DDAH2 protein]
corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]
Morphine results in decreased expression of DLG4 mRNA; Morphine results in decreased expression of DLG4 protein Morphine results in increased expression of [GRIN1 protein binds to GRIN2B protein binds to DLG4 protein]; resveratrol inhibits the reaction [Morphine results in increased expression of [GRIN1 protein binds to GRIN2B protein binds to DLG4 protein]] Morphine results in increased expression of DLG4 mRNA
Morphine results in decreased expression of DRD2 mRNA Morphine deficiency results in decreased expression of DRD2 mRNA [lead acetate co-treated with Morphine] results in increased expression of DRD2 mRNA; [lead acetate co-treated with Morphine] results in increased expression of DRD2 protein DRD2 protein affects the susceptibility to Morphine Morphine results in increased expression of DRD2 mRNA
Morphine deficiency results in increased expression of EGR1 mRNA; Morphine results in increased expression of EGR1 mRNA Morphine increases expression of Egr1 mRNA in ventral tegmental area and prefrontal cortex
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Morphine results in increased expression of EGR4 mRNA]; [Morphine results in increased activity of ELK1 protein] which results in increased expression of EGR4 mRNA EGR4 protein affects the susceptibility to Morphine
corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]]
ELK1 protein affects the susceptibility to Morphine Morphine results in increased activity of ELK1 protein [Morphine results in increased activity of ELK1 protein] which results in increased expression of EGR4 mRNA
Morphine results in increased expression of F2 protein Morphine deficiency affects the reaction [Morphine results in increased expression of F2 protein]
[FAS protein binds to FASL protein] affects the reaction [Morphine results in increased expression of IL4 protein] [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of FAS protein Morphine results in increased expression of FAS mRNA
[FAS protein binds to FASL protein] affects the reaction [Morphine results in increased expression of IL4 protein] Morphine results in increased expression of FASL mRNA
Morphine results in increased expression of FBLIM1 protein Morphine deficiency affects the reaction [Morphine results in increased expression of FBLIM1 protein]
Morphine results in decreased secretion of FGF2 protein Naloxone inhibits the reaction [Morphine results in decreased secretion of FGF2 protein]; OPRM1 protein affects the reaction [Morphine results in decreased secretion of FGF2 protein]
Morphine deficiency inhibits the reaction [Morphine deficiency inhibits the reaction [Morphine results in decreased expression of FHL2 protein]]; Morphine deficiency inhibits the reaction [Morphine results in decreased expression of FHL2 protein]
[Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased expression of FOS protein; [Morphine co-treated with Dizocilpine Maleate] inhibits the reaction [Naloxone results in increased expression of FOS protein]; Plant Extracts inhibits the reaction [Morphine results in increased expression of FOS protein] Morphine deficiency affects the expression of FOS protein Morphine results in increased expression of FOS mRNA; Morphine results in increased expression of FOS protein Morphine affects the expression of FOS mRNA 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [[Morphine co-treated with Naloxone] results in increased expression of FOS protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Morphine results in increased expression of FOS protein]; [Morphine co-treated with Cocaine] affects the expression of FOS; [Morphine co-treated with N-Methyl-3,4-methylenedioxyamphetamine] affects the expression of FOS; [Morphine co-treated with Naloxone] results in increased expression of FOS protein; [Naloxone co-treated with Morphine] results in increased expression of FOS protein; [SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; bilobalide inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; Genistein inhibits the reaction [Morphine results in increased expression of FOS protein]; Morphine affects the reaction [Formaldehyde results in increased expression of FOS protein]; N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide inhibits the reaction [Morphine results in increased expression of FOS protein]; Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; U 0126 inhibits the reaction [Morphine results in increased expression of FOS protein]
Agmatine inhibits the reaction [Morphine results in increased expression of FOSB protein] morphine increases expression of Fosb protein in the Brainstem morphine increases expression of Fosb protein in brain Morphine results in increased expression of FOSB mRNA Morphine results in increased expression of FOSB mRNA; Morphine results in increased expression of FOSB protein; Morphine results in increased expression of FOSB protein alternative form; Morphine results in increased expression of FOSB protein modified form
Morphine results in decreased expression of GNAI2 mRNA Morphine promotes the reaction [GNAI2 protein binds to RGS17 protein] Morphine results in increased expression of GNAI2 mRNA
GRIA1 protein affects the susceptibility to Morphine Morphine decreases phosphorylation of Gria1 protein in the caudate-putamen, nucleus accumbens Morphine alters expression of Gria1 protein in prefrontal cortex membrane Morphine withdrawal increases phosphorylation of Gria1 protein in hippocampal formation postsynaptic density Morphine increases expression of Gria1 protein in the striatum Morphine increases expression of Gria1 protein in the central amygdaloid nucleus Morphine promotes the reaction [CREB1 protein modified form binds to GRIA1 promoter] Morphine results in increased expression of GRIA1 mRNA Morphine results in decreased expression of GRIA1 mRNA; Morphine results in decreased expression of GRIA1 protein Morphine results in decreased phosphorylation of GRIA1 protein
GRIK1 protein affects the reaction [Morphine results in increased expression of CALCA protein]; GRIK1 protein affects the reaction [Morphine results in increased expression of PDYN protein alternative form] GRIK1 protein affects the susceptibility to Morphine
[Morphine results in increased activity of OPRM1 protein] which results in increased phosphorylation of GRIN1 protein; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of GRIN1 protein] Morphine results in increased expression of GRIN1 protein Agmatine inhibits the reaction [Morphine results in increased expression of GRIN1 protein]; Morphine results in increased expression of [GRIN1 protein binds to GRIN2B protein binds to DLG4 protein]; resveratrol inhibits the reaction [Morphine results in increased expression of [GRIN1 protein binds to GRIN2B protein binds to DLG4 protein]]; resveratrol inhibits the reaction [Morphine results in increased expression of GRIN1 protein] Morphine results in decreased phosphorylation of GRIN1 protein Morphine affects the phosphorylation of GRIN1 protein
MMP9 protein affects the reaction [Morphine results in increased phosphorylation of GRIN2B protein] Morphine results in increased expression of GRIN2B protein Morphine results in increased expression of [GRIN1 protein binds to GRIN2B protein binds to DLG4 protein]; resveratrol inhibits the reaction [Morphine results in increased expression of [GRIN1 protein binds to GRIN2B protein binds to DLG4 protein]]; resveratrol inhibits the reaction [Morphine results in increased expression of GRIN2B protein]
Morphine results in increased expression of GSK3B protein modified form Naloxone inhibits the reaction [Morphine results in increased expression of GSK3B protein modified form]
HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to MAPK1 protein]]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to MAPK3 protein]]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to RAF1 protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCB protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; HINT1 gene mutant form inhibits the reaction [Morphine results in increased phosphorylation of OPRM1 protein] HINT1 gene mutant form results in increased susceptibility to Morphine
Chlorpheniramine inhibits the reaction [HRH1 results in decreased susceptibility to Morphine]; Cimetidine inhibits the reaction [HRH1 results in decreased susceptibility to Morphine]
[zolantidine binds to and results in decreased activity of HRH2 protein] which results in increased susceptibility to Morphine; Chlorpheniramine inhibits the reaction [HRH2 results in decreased susceptibility to Morphine]; Cimetidine inhibits the reaction [HRH2 results in decreased susceptibility to Morphine] HRH2 protein results in decreased susceptibility to Morphine; HRH2 results in decreased susceptibility to Morphine
Naloxone inhibits the reaction [Morphine results in increased expression of HSPA1A mRNA] Morphine results in increased expression of HSPA1A mRNA; Morphine results in increased expression of HSPA1A protein
Morphine results in increased expression of HSPA5 protein corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]
4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Morphine]; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Morphine
Morphine results in decreased expression of ICAM1 protein alternative form Naloxone inhibits the reaction [Morphine results in decreased expression of ICAM1 protein alternative form]; phosphoramidon inhibits the reaction [Morphine results in decreased expression of ICAM1 protein alternative form]
Morphine results in decreased expression of IDH3B protein Morphine deficiency affects the reaction [Morphine results in decreased expression of IDH3B protein]
Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]; Dexamethasone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Dexamethasone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]; Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]; Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]
Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [Morphine results in increased expression of IL1B mRNA]; Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [Morphine results in increased expression of IL1B protein]; resveratrol inhibits the reaction [Morphine results in increased expression of IL1B mRNA] corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Morphine results in increased expression of IL1B protein]]; Minocycline inhibits the reaction [Morphine results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [Morphine results in increased expression of IL1B protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]] Morphine results in increased expression of IL1B mRNA; Morphine results in increased expression of IL1B protein Morphine results in increased secretion of IL1B protein
Morphine results in decreased expression of IL2 Morphine results in decreased expression of IL2 mRNA OPRM1 gene mutant form inhibits the reaction [Morphine results in decreased expression of IL2]
[FAS protein binds to FASL protein] affects the reaction [Morphine results in increased expression of IL4 protein] Morphine results in increased expression of IL4 mRNA; Morphine results in increased expression of IL4 protein CTAP octapeptide inhibits the reaction [Morphine results in increased expression of IL4 mRNA]; SB 203580 inhibits the reaction [Morphine results in increased expression of IL4 mRNA]
Morphine results in increased secretion of IL6 protein corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Morphine results in increased expression of IL6 protein]]; Minocycline inhibits the reaction [Morphine results in increased expression of IL6 protein]; Resveratrol inhibits the reaction [Morphine results in increased expression of IL6 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]] Morphine results in increased expression of IL6 mRNA; Morphine results in increased expression of IL6 protein Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [Morphine results in increased expression of IL6 mRNA]; Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [Morphine results in increased expression of IL6 protein]; resveratrol inhibits the reaction [Morphine results in increased expression of IL6 mRNA]
Acetylcysteine inhibits the reaction [Morphine results in increased phosphorylation of and results in increased activity of JUN protein]; Morphine results in increased phosphorylation of and results in increased activity of JUN protein; pyrazolanthrone inhibits the reaction [Morphine results in increased phosphorylation of and results in increased activity of JUN protein]
Morphine results in increased expression of KLF7 mRNA; Morphine results in increased expression of KLF7 protein Naloxone inhibits the reaction [Morphine results in increased expression of KLF7 mRNA]
Morphine results in decreased expression of KRT2 protein Morphine deficiency affects the reaction [Morphine results in decreased expression of KRT2 protein]
Morphine deficiency inhibits the reaction [Morphine deficiency promotes the reaction [Morphine results in increased expression of KRT33A protein]]; Morphine deficiency promotes the reaction [Morphine results in increased expression of KRT33A protein]
Morphine deficiency affects the reaction [Morphine deficiency affects the reaction [Morphine results in decreased expression of KRT8 protein]]; Morphine deficiency affects the reaction [Morphine results in decreased expression of KRT8 protein]
Morphine results in increased expression of MAPK1 protein modified form Morphine results in increased phosphorylation of MAPK1 protein [Morphine co-treated with Dehydroepiandrosterone Sulfate] results in decreased phosphorylation of MAPK1 protein; AM 251 inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to MAPK1 protein]]; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; Morphine promotes the reaction [OPRM1 protein binds to MAPK1 protein]; suvorexant inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein] Morphine deficiency results in increased phosphorylation of MAPK1 protein; Morphine results in increased phosphorylation of MAPK1 protein [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased phosphorylation of MAPK1 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; bilobalide inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased phosphorylation of MAPK1 protein]]; Oxaliplatin promotes the reaction [Morphine results in increased phosphorylation of MAPK1 protein] ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; Morphine results in increased phosphorylation of and results in increased activity of MAPK1 protein; Naloxone promotes the reaction [Morphine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; OPRD1 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]
ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; Morphine results in increased phosphorylation of and results in increased activity of MAPK3 protein; Naloxone promotes the reaction [Morphine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; OPRD1 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein] AM 251 inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to MAPK3 protein]]; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; Morphine promotes the reaction [OPRM1 protein binds to MAPK3 protein]; suvorexant inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein] Morphine deficiency results in increased phosphorylation of MAPK3 protein; Morphine results in increased phosphorylation of MAPK3 protein [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased phosphorylation of MAPK3 protein]; ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; bilobalide inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased phosphorylation of MAPK3 protein]]; Oxaliplatin promotes the reaction [Morphine results in increased phosphorylation of MAPK3 protein]
Naloxone inhibits the reaction [Morphine results in increased activity of MME protein]; phosphoramidon inhibits the reaction [Morphine results in increased activity of MME protein]
[7-nitroindazole results in decreased activity of NOS1 protein] inhibits the reaction [[Morphine co-treated with Naloxone] results in increased activity of MMP9 protein]; [Morphine co-treated with Naloxone] results in increased activity of MMP9 protein; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of GRIN1 protein]; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of GRIN2B protein]; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; MMP9 protein affects the reaction [Morphine results in increased phosphorylation of MAPK3 protein] Morphine results in increased activity of MMP9 protein
Morphine results in increased phosphorylation of NFKBIA protein NFKBIA protein affects the susceptibility to Morphine Morphine results in increased expression of NFKBIA protein Morphine results in increased degradation of NFKBIA protein Morphine results in increased expression of NFKBIA mRNA; Morphine results in increased expression of NFKBIA protein Calcium affects the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; CTAP octapeptide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; CTAP octapeptide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Morphine inhibits the reaction [Doxorubicin results in increased degradation of NFKBIA protein]; Morphine inhibits the reaction [TNF protein results in increased ubiquitination of and results in increased degradation of NFKBIA protein]; USP15 mutant form inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]
corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]; Minocycline inhibits the reaction [Morphine results in increased expression of NLRP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]
[7-nitroindazole results in decreased activity of NOS1 protein] inhibits the reaction [[Morphine co-treated with Naloxone] results in increased activity of MMP9 protein] Morphine results in decreased expression of NOS1 protein PENK protein alternative form inhibits the reaction [Morphine results in increased expression of NOS1 protein]
Morphine results in increased expression of NOS2 mRNA; Morphine results in increased expression of NOS2 protein corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; Minocycline inhibits the reaction [Morphine results in increased expression of NOS2 protein]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [Morphine results in increased expression of NOS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]] NOS2 protein affects the susceptibility to Morphine
BDNF protein inhibits the reaction [NR4A2 protein affects the susceptibility to Morphine] Morphine results in decreased expression of NR4A2 mRNA Morphine inhibits the reaction [CREB1 protein modified form binds to NR4A2 promoter]; Morphine inhibits the reaction [NR4A2 protein binds to BDNF promoter]
ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]; Morphine promotes the reaction [ARL6IP5 protein binds to OPRD1 protein]; OPRD1 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]; OPRD1 mutant form inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]; OPRD1 mutant form inhibits the reaction [Morphine results in increased phosphorylation of PPP1R1B protein] ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]]; Morphine promotes the reaction [ARL6IP5 protein binds to OPRD1 protein] Morphine binds to OPRD1 protein
Morphine affects the activity of OPRK1 protein Morphine results in increased activity of OPRK1 protein Morphine results in increased expression of OPRK1 mRNA Morphine binds to OPRK1 protein Morphine inhibits the reaction [Zymosan results in decreased expression of OPRK1 mRNA]
[[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [COMT gene SNP co-treated with OPRM1 gene SNP] affects the susceptibility to Morphine; [OPRM1 protein co-treated with Morphine] results in increased activity of ARRB2 protein; Morphine binds to and results in increased activity of OPRM1 protein; Morphine inhibits the reaction [Tretinoin results in increased expression of OPRM1 mRNA]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Tretinoin results in increased expression of OPRM1 mRNA]]; OPRM1 protein affects the reaction [Morphine results in decreased secretion of FGF2 protein] Morphine results in increased phosphorylation of OPRM1 protein Morphine results in increased activity of OPRM1 protein Morphine results in decreased expression of OPRM1 mRNA OPRM1 affects the susceptibility to Morphine; OPRM1 protein affects the susceptibility to Morphine [Morphine results in increased activity of OPRM1 protein] which results in increased phosphorylation of GRIN1 protein; [phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Morphine; [Zymosan co-treated with Morphine] results in increased expression of OPRM1 mRNA; Dizocilpine Maleate inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]]; Dizocilpine Maleate inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to MAPK1 protein]]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to MAPK3 protein]]; HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to RAF1 protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCB protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; HINT1 gene mutant form inhibits the reaction [Morphine results in increased phosphorylation of OPRM1 protein]; Morphine affects the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein]; Morphine binds to and affects the activity of OPRM1 protein; Morphine binds to and results in increased activity of OPRM1 protein; Morphine promotes the reaction [OPRM1 protein binds to MAPK1 protein]; Morphine promotes the reaction [OPRM1 protein binds to MAPK3 protein]; Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]; Morphine promotes the reaction [OPRM1 protein binds to PRKCB protein]; Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]; Morphine promotes the reaction [OPRM1 protein binds to RAF1 protein]; Naloxone inhibits the reaction [Morphine results in increased phosphorylation of OPRM1 protein]; OPRM1 gene mutant form inhibits the reaction [Morphine results in decreased expression of IFNG]; OPRM1 gene mutant form inhibits the reaction [Morphine results in decreased expression of IL2]; Tetradecanoylphorbol Acetate inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; valyl-prolyl-aspartyl-prolyl-arginine inhibits the reaction [Morphine results in increased activity of OPRM1 protein] Morphine results in increased expression of OPRM1 protein Morphine binds to OPRM1 protein OPRM1 affects the activity of Morphine [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] inhibits the reaction [Morphine results in increased abundance of 3,4-Dihydroxyphenylacetic Acid]; [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] inhibits the reaction [Morphine results in increased abundance of Homovanillic Acid]; [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Morphine; [Morphine binds to and results in increased activity of OPRM1 protein] which results in increased activity of ARRB2 protein; [naloxonazine binds to and results in decreased activity of OPRM1 protein] which affects the susceptibility to Morphine; [naloxonazine binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Morphine; Morphine affects the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein]; Morphine binds to and affects the activity of OPRM1 protein; Morphine binds to and results in increased activity of OPRM1 protein OPRM1 exon SNP results in decreased susceptibility to Morphine Morphine affects the activity of OPRM1 protein
PDGFB protein inhibits the reaction [Morphine results in decreased expression of BCL2 protein]; PDGFB protein inhibits the reaction [Morphine results in increased activity of CASP3 protein]; PDGFB protein inhibits the reaction [Morphine results in increased expression of BAX protein] PDGFB protein results in decreased susceptibility to Morphine
Morphine results in increased expression of PDHB protein Morphine deficiency affects the reaction [Morphine results in increased expression of PDHB protein]
Morphine results in increased expression of PDYN protein alternative form Morphine deficiency results in decreased expression of PDYN mRNA Morphine results in decreased expression of PDYN mRNA [Zymosan co-treated with Morphine] results in increased expression of PDYN mRNA; GRIK1 protein affects the reaction [Morphine results in increased expression of PDYN protein alternative form]
Morphine inhibits the reaction [Formaldehyde results in increased expression of PENK mRNA]; PENK protein alternative form inhibits the reaction [Morphine results in increased expression of CALCA protein]; PENK protein alternative form inhibits the reaction [Morphine results in increased expression of NOS1 protein]; PENK protein alternative form inhibits the reaction [Morphine results in increased expression of PRKCG protein] Morphine deficiency results in decreased expression of PENK mRNA
[Fentanyl co-treated with Morphine] results in decreased expression of POMC protein alternative form Morphine deficiency results in increased secretion of POMC protein modified form [Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased secretion of POMC protein modified form]; [Morphine co-treated with Naloxone] results in increased secretion of POMC protein; Capsaicin inhibits the reaction [[Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein]; Capsaicin inhibits the reaction [[Morphine co-treated with Naloxone] results in increased secretion of POMC protein] [Zymosan co-treated with Morphine] results in increased expression of POMC mRNA Morphine results in increased expression of POMC mRNA
Morphine affects the expression of PPP1R1B protein modified form ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of PPP1R1B protein] ARL6IP5 mutant form inhibits the reaction [Morphine results in increased phosphorylation of PPP1R1B protein]; OPRD1 mutant form inhibits the reaction [Morphine results in increased phosphorylation of PPP1R1B protein]
Dizocilpine Maleate inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]]; Morphine promotes the reaction [OPRM1 protein binds to PRKCA protein]
HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCB protein]]; Morphine promotes the reaction [OPRM1 protein binds to PRKCB protein]
PENK protein alternative form inhibits the reaction [Morphine results in increased expression of PRKCG protein] Dizocilpine Maleate inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; HINT1 gene mutant form inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]]; Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Morphine promotes the reaction [OPRM1 protein binds to PRKCG protein]] Morphine results in increased expression of PRKCG protein modified form
Morphine results in decreased expression of PTGS1 mRNA Morphine results in increased expression of PTGS1 mRNA Minocycline inhibits the reaction [Morphine results in increased expression of PTGS1 mRNA]
Morphine results in increased expression of PTGS2 protein [nimesulide results in decreased activity of PTGS2 protein] which results in increased susceptibility to Morphine [Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]; Minocycline inhibits the reaction [Morphine results in increased expression of PTGS2 protein]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]
Morphine results in decreased expression of PYCARD mRNA Morphine results in increased expression of PYCARD protein corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]; Minocycline inhibits the reaction [Morphine results in increased expression of PYCARD protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]
RAF1 protein affects the susceptibility to Morphine HINT1 affects the reaction [Morphine promotes the reaction [OPRM1 protein binds to RAF1 protein]]; Morphine promotes the reaction [OPRM1 protein binds to RAF1 protein]
Morphine inhibits the reaction [Doxorubicin affects the localization of RELA protein] Colforsin inhibits the reaction [Morphine results in increased phosphorylation of RELA protein]
Morphine results in decreased expression of SELL protein alternative form Naloxone inhibits the reaction [Morphine results in decreased expression of SELL protein alternative form]; phosphoramidon inhibits the reaction [Morphine results in decreased expression of SELL protein alternative form]
Morphine deficiency inhibits the reaction [Morphine deficiency inhibits the reaction [Morphine results in decreased expression of SEPTIN7 protein]]; Morphine deficiency inhibits the reaction [Morphine results in decreased expression of SEPTIN7 protein]
[NNC 711 results in decreased activity of SLC6A1 protein] which affects the susceptibility to Morphine SLC6A1 protein affects the susceptibility to Morphine
Morphine affects the reaction [SMPD1 protein affects the abundance of Ceramides]; Naloxone inhibits the reaction [Morphine results in increased expression of SMPD1 protein]
Morphine results in increased expression of SMPX protein Morphine deficiency affects the reaction [Morphine results in increased expression of SMPX protein]
Morphine deficiency results in increased expression of TAC1 mRNA; Morphine results in increased expression of TAC1 mRNA Morphine results in increased expression of TAC1 protein Morphine promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]; Naloxone inhibits the reaction [Morphine results in increased expression of TAC1 protein]
[SR 140333 binds to and results in decreased activity of TACR1 protein] which results in increased susceptibility to Morphine; substance P-saporin inhibits the reaction [Morphine results in increased expression of TACR1 protein] Morphine results in decreased expression of TACR1 protein
Morphine results in increased expression of and results in increased localization of TGFB1 protein; TGFB1 protein affects the reaction [Morphine results in increased expression of and results in increased localization of TGFB1 protein]; TGFB1 protein affects the reaction [Morphine results in increased expression of BAX protein]
Morphine results in increased expression of TH protein [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency results in increased phosphorylation of TH protein]; [Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein; Agmatine inhibits the reaction [Morphine results in increased expression of TH protein]; Morphine promotes the reaction [CREB1 protein modified form binds to TH promoter] Morphine results in decreased expression of TH protein [Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein; CRHR1 gene mutant form inhibits the reaction [[Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein]
Morphine results in increased expression of TLR2 mRNA; Morphine results in increased expression of TLR2 protein corilagin inhibits the reaction [Morphine results in increased expression of TLR2 mRNA]; corilagin inhibits the reaction [Morphine results in increased expression of TLR2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]]
Morphine binds to TLR4 protein Morphine results in increased expression of TLR4 protein dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Morphine results in increased expression of TLR4 protein]]; Resveratrol inhibits the reaction [Morphine results in increased expression of TLR4 protein] Morphine affects the susceptibility to TLR4 protein Naloxone affects the reaction [Morphine binds to TLR4 protein]
Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [Morphine results in increased expression of TNF mRNA]; Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [Morphine results in increased expression of TNF protein]; Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]; Resveratrol inhibits the reaction [Morphine results in increased expression of TNF mRNA] corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Morphine results in increased expression of TNF protein]]; Minocycline inhibits the reaction [Morphine results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Morphine results in increased expression of TNF protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]] Calcium affects the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; CTAP octapeptide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; CTAP octapeptide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; CTAP octapeptide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]; Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Morphine inhibits the reaction [TNF protein results in increased ubiquitination of and results in increased degradation of NFKBIA protein]; USP15 mutant form inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]] Morphine results in increased expression of TNF mRNA; Morphine results in increased expression of TNF protein Morphine results in increased secretion of TNF protein
[Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of BAX protein; [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of CDKN1A protein; [Morphine results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of FAS protein; Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form]; Morphine results in increased phosphorylation of and results in increased activity of TP53 protein; Morphine results in increased phosphorylation of and results in increased stability of TP53 protein; Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form]]; Naloxone inhibits the reaction [Morphine results in increased expression of TP53]; Naloxone inhibits the reaction [Morphine results in increased phosphorylation of TP53 protein] Morphine results in increased expression of TP53 mRNA
[N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide binds to and results in decreased activity of TRPV1 protein] which results in decreased susceptibility to Morphine Morphine affects the activity of TRPV1 protein Morphine results in increased expression of TRPV1; Morphine results in increased expression of TRPV1 protein TRPV1 protein affects the susceptibility to Morphine
Morphine results in decreased expression of TTR protein Morphine deficiency affects the reaction [Morphine results in decreased expression of TTR protein]
UGT2B7 affects the metabolism of Morphine; UGT2B7 protein affects the metabolism of Morphine UGT2B7 protein results in increased glucuronidation of Morphine
Calcium affects the reaction [Morphine results in increased expression of USP15 mRNA]; CTAP octapeptide inhibits the reaction [Morphine results in increased expression of USP15 mRNA]; USP15 mutant form inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]] Morphine results in increased expression of USP15 mRNA; Morphine results in increased expression of USP15 protein
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin inhibits the reaction [morphine-3-glucuronide results in increased activity of TLR4 protein]; Lipopolysaccharides inhibits the reaction [morphine-3-glucuronide results in increased activity of TLR4 protein] morphine-3-glucuronide results in increased expression of TLR4 mRNA
[nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; nalmefene binds to and results in decreased activity of OPRM1 protein
Nalorphine results in increased expression of PRL protein Bromocriptine inhibits the reaction [Nalorphine results in increased expression of PRL protein]
Naloxone promotes the reaction [AGT protein results in increased expression of CRH protein]; Naloxone promotes the reaction [AGT protein results in increased expression of FOS protein]; Naloxone promotes the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Naloxone promotes the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]
Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in decreased expression of BCL2 protein]] Naloxone results in increased expression of BCL2 protein
Naloxone affects the activity of CALCA protein Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [Potassium Chloride results in increased secretion of CALCA protein]]; Naloxone inhibits the reaction [Fentanyl inhibits the reaction [Potassium Chloride results in increased secretion of CALCA protein]]
Naloxone inhibits the reaction [Morphine results in increased activity of CASP3 protein]; Naloxone inhibits the reaction [Morphine results in increased expression of CASP3 protein alternative form]
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone results in increased phosphorylation of TH protein]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone results in increased secretion of POMC protein modified form]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] which results in decreased susceptibility to Naloxone CRHR1 gene mutant form results in increased susceptibility to Naloxone CRHR1 gene mutant form inhibits the reaction [[Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein]
[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP]
[Morphine co-treated with Dizocilpine Maleate] inhibits the reaction [Naloxone results in increased expression of FOS protein] 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [[Morphine co-treated with Naloxone] results in increased expression of FOS protein]; [Morphine co-treated with Naloxone] results in increased expression of FOS protein; [Naloxone co-treated with Morphine] results in increased expression of FOS protein; Naloxone promotes the reaction [AGT protein results in increased expression of FOS protein]; Pentobarbital promotes the reaction [Naloxone results in increased expression of FOS protein]; SL 327 inhibits the reaction [Naloxone results in increased expression of FOS protein]
Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]
Naloxone results in increased expression of LHB protein Naloxone affects the expression of LHB protein Naloxone affects the expression of and affects the secretion of LHB protein
Naloxone promotes the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Naloxone results in increased phosphorylation of and results in increased activity of MAPK1 protein Naloxone results in increased phosphorylation of MAPK1 protein Naloxone promotes the reaction [Morphine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Naloxone promotes the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]; Naloxone results in increased phosphorylation of and results in increased activity of MAPK3 protein Naloxone results in increased phosphorylation of MAPK3 protein Naloxone promotes the reaction [Morphine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[7-nitroindazole results in decreased activity of NOS1 protein] inhibits the reaction [[Morphine co-treated with Naloxone] results in increased activity of MMP9 protein]; [Morphine co-treated with Naloxone] results in increased activity of MMP9 protein
[7-nitroindazole results in decreased activity of NOS1 protein] inhibits the reaction [[Morphine co-treated with Naloxone] results in increased activity of MMP9 protein]
[[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Tretinoin results in increased expression of OPRM1 mRNA]] Naloxone inhibits the reaction [Morphine results in increased phosphorylation of OPRM1 protein] Naloxone binds to OPRM1 protein [Naloxone binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Clonidine; [Naloxone binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; [Naloxone binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to N(6)-cyclopentyladenosine; Cannabidiol promotes the reaction [Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]]; Dronabinol promotes the reaction [Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]]; Naloxone binds to and results in decreased activity of OPRM1 protein; Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]
[Clonidine results in increased expression of POMC protein] which results in increased susceptibility to Naloxone; Naloxone binds to and results in increased activity of POMC protein alternative form Naloxone results in increased secretion of POMC protein modified form [Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone results in increased secretion of POMC protein modified form]; [Morphine co-treated with Naloxone] results in increased secretion of POMC protein; Capsaicin inhibits the reaction [[Clonidine co-treated with Naloxone co-treated with Morphine] results in increased secretion of POMC protein]; Capsaicin inhibits the reaction [[Morphine co-treated with Naloxone] results in increased secretion of POMC protein] Naloxone results in increased expression of POMC protein alternative form
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone results in increased phosphorylation of TH protein]; [Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein [Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein; CRHR1 gene mutant form inhibits the reaction [[Morphine co-treated with Naloxone] results in increased phosphorylation of TH protein]
Naloxone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Naloxone results in decreased expression of TNF protein
Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in increased expression of TP53 protein modified form]]; Naloxone inhibits the reaction [Morphine results in increased expression of TP53]; Naloxone inhibits the reaction [Morphine results in increased phosphorylation of TP53 protein] Naloxone results in decreased expression of TP53 mRNA
[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; [ALDH2 protein affects the abundance of Tetrahydropapaveroline] which affects the susceptibility to Cocaine; [CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Oxycodone affects the expression of CYP2B2 mRNA Oxycodone results in increased expression of CYP2B2 mRNA; Oxycodone results in increased expression of CYP2B2 protein
CYP2D6 gene polymorphism affects the susceptibility to Oxycodone [Quinidine results in decreased activity of CYP2D6 protein] which affects the susceptibility to Oxycodone
Oxycodone inhibits the reaction [CYP3A2 protein results in increased hydroxylation of Testosterone] CYP3A4 protein alternative form affects the metabolism of Oxycodone telithromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Oxycodone] Oxycodone results in decreased expression of CYP3A2 mRNA; Oxycodone results in decreased expression of CYP3A2 protein
Oxymorphone affects the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein]; Oxymorphone binds to and affects the activity of OPRM1 protein
palmatine inhibits the reaction [ABCB1A protein results in increased export of Fluorescent Dyes] ABCB1A protein results in increased export of palmatine palmatine results in increased expression of ABCB1A mRNA
palmatine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; palmatine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] palmatine results in increased secretion of IL1B protein
palmatine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; palmatine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] palmatine results in increased secretion of IL6 protein
palmatine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; palmatine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Papaverine inhibits the reaction [Isoproterenol affects the localization of LIPE protein]; Papaverine inhibits the reaction [Isoproterenol results in increased activity of LIPE protein]
Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]
sanguinarine promotes the reaction [AHR protein binds to ARNT protein]; sanguinarine results in increased activity of and affects the localization of AHR protein; sanguinarine results in increased localization of and results in increased activity of AHR protein
sanguinarine results in increased expression of BAX protein sanguinarine results in increased expression of BAX mRNA; sanguinarine results in increased expression of BAX protein NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX protein]
sanguinarine results in decreased expression of BCL2 protein sanguinarine results in decreased expression of BCL2 mRNA; sanguinarine results in decreased expression of BCL2 protein NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 protein] [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of BCL2 protein
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BCL2L14 mRNA sanguinarine results in increased expression of BCL2L14 mRNA
[Acetylcysteine results in decreased abundance of Reactive Oxygen Species] inhibits the reaction [sanguinarine results in increased cleavage of BID protein]
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CASP1 mRNA sanguinarine results in increased expression of CASP1 mRNA
sanguinarine results in decreased expression of CASP3 protein alternative form [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine co-treated with arsenic trioxide] results in increased activity of CASP3 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in increased activity of CASP3 protein sanguinarine results in increased activity of CASP3 protein
sanguinarine results in increased activity of CASP8 protein [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sanguinarine co-treated with arsenic trioxide] results in increased activity of CASP8 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein
sanguinarine results in decreased expression of CASP9 protein alternative form [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in increased activity of CASP9 protein sanguinarine results in increased activity of CASP9 protein
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of CAT protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of CAT protein
sanguinarine inhibits the reaction [Methylcholanthrene results in increased activity of CRYZ protein] sanguinarine results in decreased activity of CRYZ protein
sanguinarine results in decreased activity of CYP1A1 protein sanguinarine inhibits the reaction [Methylcholanthrene results in increased expression of and results in increased activity of CYP1A1 protein]; sanguinarine results in decreased expression of and results in decreased activity of CYP1A1 protein sanguinarine results in increased expression of CYP1A1 mRNA; sanguinarine results in increased expression of CYP1A1 protein sanguinarine results in increased activity of CYP1A1 protein
sanguinarine inhibits the reaction [Methylcholanthrene results in increased expression of and results in increased activity of CYP1A2 protein]; sanguinarine results in decreased expression of and results in decreased activity of CYP1A2 protein
sanguinarine promotes the reaction [Reactive Oxygen Species results in increased activity of EGR1 protein] sanguinarine results in increased expression of EGR1 protein sanguinarine results in decreased expression of EGR1 protein
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of GSR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of GSR protein
sanguinarine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]; sanguinarine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GSTP1 mRNA]; sanguinarine inhibits the reaction [TNF protein results in increased expression of GSTP1 mRNA] sanguinarine results in increased expression of GSTP1 protein
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of HAL protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of HAL protein
sanguinarine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein]
[sanguinarine co-treated with arsenic trioxide] results in increased expression of NLRP1 mRNA sanguinarine results in increased expression of NLRP1 mRNA
sanguinarine results in decreased expression of NQO1 mRNA; sanguinarine results in decreased expression of NQO1 protein NQO1 protein results in increased reduction of sanguinarine NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 protein]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX protein]
sanguinarine inhibits the reaction [Phenobarbital results in increased activity of POR protein]; sanguinarine promotes the reaction [Methylcholanthrene results in decreased activity of POR protein] sanguinarine results in decreased activity of POR protein
[sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sanguinarine co-treated with arsenic trioxide] results in increased expression of TNFSF10 mRNA; [sanguinarine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; TNFSF10 protein results in increased susceptibility to [arsenic trioxide co-treated with sanguinarine] sanguinarine results in increased expression of TNFSF10 mRNA
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of TYR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of TYR protein
sinomenine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of ATG10 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of ATG10 protein]
sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of BECN1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of BECN1 protein]
sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]
sinomenine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
sinomenine inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]
sinomenine inhibits the reaction [IFNG protein results in decreased expression of ARG1 mRNA]; sinomenine inhibits the reaction [IFNG protein results in decreased expression of IL10 mRNA]; sinomenine inhibits the reaction [IFNG protein results in decreased expression of IL10 protein]; sinomenine inhibits the reaction [IFNG protein results in decreased expression of TGFB1 mRNA]; sinomenine inhibits the reaction [IFNG protein results in decreased expression of TGFB1 protein]; sinomenine inhibits the reaction [IFNG protein results in increased expression of CCL2 mRNA]; sinomenine inhibits the reaction [IFNG protein results in increased expression of IL1B mRNA]; sinomenine inhibits the reaction [IFNG protein results in increased expression of IL1B protein]; sinomenine inhibits the reaction [IFNG protein results in increased expression of TNF mRNA]; sinomenine inhibits the reaction [IFNG protein results in increased expression of TNF protein]; sinomenine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG mRNA]; sinomenine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]
sinomenine inhibits the reaction [IFNG protein results in decreased expression of IL10 mRNA]; sinomenine inhibits the reaction [IFNG protein results in decreased expression of IL10 protein]
sinomenine inhibits the reaction [IFNG protein results in increased expression of IL1B mRNA]; sinomenine inhibits the reaction [IFNG protein results in increased expression of IL1B protein]
sinomenine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MAF mRNA]; sinomenine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MAF protein]
sinomenine inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased phosphorylation of PIK3CB protein]
sinomenine inhibits the reaction [IFNG protein results in decreased expression of TGFB1 mRNA]; sinomenine inhibits the reaction [IFNG protein results in decreased expression of TGFB1 protein] sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of ATG10 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of ATG10 protein]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of BECN1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of BECN1 protein]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of TGFBR1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of TGFBR1 protein]; sinomenine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; sinomenine inhibits the reaction [TGFB1 protein results in increased phosphorylation of PIK3CB protein]
sinomenine inhibits the reaction [TGFB1 protein results in increased expression of TGFBR1 mRNA]; sinomenine inhibits the reaction [TGFB1 protein results in increased expression of TGFBR1 protein]
sinomenine inhibits the reaction [IFNG protein results in increased expression of TNF mRNA]; sinomenine inhibits the reaction [IFNG protein results in increased expression of TNF protein]; sinomenine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]; sinomenine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
tetrahydropalmatine results in decreased expression of ESR1 mRNA tetrahydropalmatine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of ESR1 mRNA]
tetrahydropalmatine inhibits the reaction [SLC22A1 protein results in increased uptake of Monocrotaline]; tetrahydropalmatine inhibits the reaction [SLC22A1 protein results in increased uptake of retrorsine]
[ABCB1A protein mutant form co-treated with ABCB1B protein mutant form] results in increased susceptibility to trabectedin trabectedin results in increased expression of ABCB1A mRNA
[ABCB1A protein mutant form co-treated with ABCB1B protein mutant form] results in increased susceptibility to trabectedin trabectedin results in increased expression of ABCB1B mRNA
Tubocurarine promotes the reaction [Dichlorvos results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [haloxon results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]
Tubocurarine inhibits the reaction [[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form]; Tubocurarine inhibits the reaction [Nicotine results in increased metabolism of APP protein]
Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA2 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]]
Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]; Tubocurarine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA3 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]]; Tubocurarine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]
Tubocurarine binds to and results in decreased activity of CHRNA7 protein; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; Tubocurarine inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]
Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein] Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA3 protein]]
Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]; Tubocurarine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]]; Tubocurarine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
Tubocurarine results in increased expression of CNTN1 mRNA Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA] Tubocurarine results in decreased expression of CNTN1 mRNA
Tubocurarine results in decreased expression of GOLGA4 mRNA Tubocurarine inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]
Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]
Tubocurarine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 protein]
Tubocurarine results in decreased expression of POU5F1 mRNA Tubocurarine inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]
Tubocurarine inhibits the reaction [PTMA protein results in decreased expression of BCL2]; Tubocurarine inhibits the reaction [PTMA protein results in increased expression of FAS]
browse the term
